Displaying 1 - 12 of 38
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
Displaying 1 - 12 of 38